We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

433 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 127 increasing their positions, 101 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 60

60% more capital invested

Capital invested by funds: $2.2B → $3.52B (+$1.32B)

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

26% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 101

9% more funds holding

Funds holding: 396 → 433 (+37)

8.4% more ownership

Funds ownership: 75.39% → 83.79% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
433
Holders Change
+37
Holders Change %
+9.34%
% of All Funds
5.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
101
Increased
127
Reduced
101
Closed
60
Calls
$244M
Puts
$186M
Net Calls
+$58.2M
Net Calls Change
+$37.5M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$134M
2
OAG
Orbis Allan Gray
Bermuda
+$46.5M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.7M
4
State Street
State Street
Massachusetts
+$33.3M
5
UBS Group
UBS Group
Switzerland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$38.2M
2
Morgan Stanley
Morgan Stanley
New York
-$30.5M
3
BBA
Baker Bros. Advisors
New York
-$22.3M
4
Millennium Management
Millennium Management
New York
-$19.9M
5
Capital International Investors
Capital International Investors
California
-$18.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
376
Gould Capital
Washington
$3.4K – – –
GWS
377
Greykasell Wealth Strategies
California
$3.31K – – –
BIA
378
Bell Investment Advisors
California
$3.31K +$2.63K +68 New
MSG
379
Main Street Group
Virginia
$3.02K – – –
RIL
380
Rothschild Investment LLC
Illinois
$2.92K – – –
LI
381
Louisbourg Investments
New Brunswick, Canada
$2.92K +$2.32K +60 New
PS
382
Principal Securities
Iowa
$2.87K -$464 -12 -17%
TIM
383
Total Investment Management
Arizona
$2.87K +$2.28K +59 New
IA
384
IFS Advisors
Kansas
$2.87K – – –
OLVIG
385
Oliver Lagore Vanvalin Investment Group
Michigan
$2.55K +$2.9K +75 New
CB
386
Community Bank
New York
$2.43K – – –
AssetMark Inc
387
AssetMark Inc
California
$2.09K +$1.24K +32 +291%
CAL
388
Capital Analysts LLC
Pennsylvania
$2K – – –
MWM
389
Mascoma Wealth Management
New Hampshire
$1.95K – – –
TFA
390
Toth Financial Advisory
Virginia
$1.95K +$1.55K +40 New
MCM
391
MV Capital Management
Maryland
$1.8K -$310 -8 -18%
SIC
392
SJS Investment Consulting
Ohio
$1.65K – – –
KA
393
Kozak & Associates
Colorado
$1.56K – – –
PP
394
Pacifica Partners
Canada
$1.43K – – –
AIC
395
Archer Investment Corporation
Indiana
$973 – – –
MWM
396
MorganRosel Wealth Management
Colorado
$973 – – –
VFM
397
Vision Financial Markets
Connecticut
$973 – – –
MAWAG
398
Mid-American Wealth Advisory Group
Missouri
$973 +$774 +20 New
AAP
399
Arax Advisory Partners
Colorado
$876 -$967 -25 -58%
CMBA
400
C.M. Bidwell & Associates
Hawaii
$876 – – –
14 15
16
17 18

CRSP Hedge Fund Activity: Q2 2025 in Review

433 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CRSP positions and 60 closed out — a net gain of 41 holders — while 127 added to existing stakes and 101 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 433 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 396 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 101 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +41 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.